Drug Name: Omlonti
Active Ingredient: oomidenepag isopropyl ophthalmic solution
Indications: To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension
Approval Date: 9/22/2022
Company: Santen Incorporated
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215092s000lbl.pdf